ArticleFrontiers in medicine2025
Sump syndrome following hepaticojejunostomy: a case report of IgG4-related sclerosing cholangitis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report presents a case of IgG4-related sclerosing cholangitis (IgG4-SC) in a patient who ultimately died from a complex postoperative infection. The patient was a 59-year-old male who underwent resection of a hilar lesion and Roux-en-Y hepaticojejunostomy (RYHJ) for obstructive jaundice 7 years ago, with postoperative pathology confirming IgG4-SC. However, from 4 months after surgery, the patient experienced recurrent fever episodes that persisted for 7 years. The clinical presentation was consistent with sump syndrome. Both recurrent infections and IgG4-SC disease activity can elevate IgG4 levels, complicating clinical assessment. Despite aggressive antibiotic therapy combined with immunosuppressive treatment, the infections recurred. The patient eventually succumbed to sepsis in August 2025, triggered by recurrent cholangitis. This case underscores the importance of differentiating IgG4-SC from hilar cholangiocarcinoma (HC) to avoid unnecessary surgery. Moreover, it highlights that in post-hepaticojejunostomy patients, distinguishing whether elevated IgG4 levels signify disease activity or are secondary to infection is essential for guiding therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.